Q1 Earnings Forecast for Masimo Issued By Zacks Research

Masimo Co. (NASDAQ:MASI - Free Report) - Stock analysts at Zacks Research issued their Q1 2025 EPS estimates for Masimo in a report released on Tuesday, March 18th. Zacks Research analyst I. Bandyopadhyay forecasts that the medical equipment provider will post earnings per share of $1.25 for the quarter. The consensus estimate for Masimo's current full-year earnings is $4.10 per share. Zacks Research also issued estimates for Masimo's Q2 2025 earnings at $1.28 EPS, Q3 2025 earnings at $1.31 EPS, Q4 2025 earnings at $1.47 EPS, FY2025 earnings at $5.32 EPS, Q1 2026 earnings at $1.41 EPS, Q2 2026 earnings at $1.45 EPS, Q3 2026 earnings at $1.44 EPS, Q4 2026 earnings at $1.60 EPS and FY2026 earnings at $5.90 EPS.

MASI has been the subject of a number of other research reports. Raymond James upped their price objective on Masimo from $170.00 to $194.00 and gave the stock an "outperform" rating in a research note on Friday, December 27th. Needham & Company LLC restated a "hold" rating on shares of Masimo in a research note on Wednesday, February 26th. Wells Fargo & Company increased their price objective on shares of Masimo from $193.00 to $205.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. Finally, Piper Sandler boosted their target price on shares of Masimo from $210.00 to $215.00 and gave the stock an "overweight" rating in a report on Wednesday, February 26th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, Masimo presently has an average rating of "Moderate Buy" and an average price target of $194.80.

Remove Ads

Masimo Stock Performance

Masimo stock traded up $2.09 during midday trading on Friday, hitting $169.70. The stock had a trading volume of 476,981 shares, compared to its average volume of 625,501. The company has a market capitalization of $9.16 billion, a PE ratio of 117.03 and a beta of 1.04. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. The firm's fifty day moving average is $175.03 and its two-hundred day moving average is $160.20. Masimo has a 52-week low of $101.61 and a 52-week high of $194.88.

Masimo (NASDAQ:MASI - Get Free Report) last released its earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.42 by $0.38. The company had revenue of $600.70 million for the quarter, compared to the consensus estimate of $593.35 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%.

Insider Buying and Selling at Masimo

In other Masimo news, COO Bilal Muhsin sold 30,000 shares of Masimo stock in a transaction on Monday, March 10th. The shares were sold at an average price of $167.49, for a total value of $5,024,700.00. Following the completion of the transaction, the chief operating officer now directly owns 24,172 shares of the company's stock, valued at $4,048,568.28. This trade represents a 55.38 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Craig B. Reynolds sold 2,053 shares of the business's stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $166.13, for a total transaction of $341,064.89. Following the completion of the sale, the director now owns 16,581 shares in the company, valued at approximately $2,754,601.53. This trade represents a 11.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 9.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Smartleaf Asset Management LLC grew its stake in Masimo by 31.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 250 shares of the medical equipment provider's stock worth $42,000 after acquiring an additional 60 shares in the last quarter. EverSource Wealth Advisors LLC grew its stake in Masimo by 40.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider's stock worth $37,000 after purchasing an additional 64 shares in the last quarter. Blue Trust Inc. increased its holdings in Masimo by 56.3% during the 4th quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider's stock worth $33,000 after purchasing an additional 71 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its position in Masimo by 0.8% during the 4th quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 9,815 shares of the medical equipment provider's stock valued at $1,622,000 after purchasing an additional 82 shares in the last quarter. Finally, Thrivent Financial for Lutherans lifted its holdings in shares of Masimo by 0.8% in the 4th quarter. Thrivent Financial for Lutherans now owns 10,456 shares of the medical equipment provider's stock worth $1,728,000 after buying an additional 83 shares during the period. Hedge funds and other institutional investors own 85.96% of the company's stock.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.